Epigenetics and celebrating the International Year of Crystallography, and we would welcome suggestions from readers for other topics to cover in future.
We will be introducing a new 'state-of-the-art' Minireview Series where leaders in particular research areas will give their personal perspectives on major unsolved questions and key issues that remain to be addressed in their respective fields. I also aim to strengthen our coverage of research areas that are currently somewhat underrepresented in the FEBS Journal, including (but certainly not limited to): autophagy, cell death, cell cycle, DNA damage and DNA repair, epigenetics, inflammation, infection and immunity, oncogenesis, organelle dynamics, protein modification and degradation, signal transduction and other areas of broad biological interest. I would especially encourage submissions in these areas to ensure that we publish across the whole spectrum of molecular and cellular life sciences.
As regular readers will know, the FEBS Journal is a multidisciplinary one and endeavors to cover the full breadth of research being conducted within the molecular life sciences. In addition to the greater visibility that comes with publishing in a multidisciplinary journal, the FEBS Journal offers many additional benefits to authors. These include: rapid peer review, rapid publication upon acceptance, and no page or color figure charges. More importantly, the FEBS Journal offers high visibility of published papers due to the relatively small number of articles published in each issue. Help us to continue to build the profile and prestige of the FEBS Journal by submitting your excellent papers for consideration. In this issue we have many excellent papers and we also begin a new initiative, 'Editor's choice', where we have selected one paper for particular mention, with an accompanying summary by the handling editor. The Editor's choice paper in this issue concerns LRRK2-stimulated phosphorylation of tau by GSK-3 b which has implications for Parkinson's Disease [7] . We also have papers on the role of Survivin in resistance to cis-platin therapy in cancer [8] , an analysis of the positional bias of mutations during affinity maturation of antibodies [9] , as well as an excellent review by Geoffrey Faulkner and colleagues on the possible links between retrotransposons and cancer [10] .
In conclusion, I am honored and excited to be taking up the baton from Richard Perham as the new Editor-in-Chief of the FEBS Journal. I look forward to the challenge of building upon Richard's considerable legacy at the journal to increase the breadth of areas that we publish in, as well as to continue to build the quality and impact of the papers we publish. In this regard, I would greatly encourage submission of your high quality manuscripts to the journal, as well as your suggestions for timely review topics and Special Issues. I look forward to meeting many of you at various conferences in the coming months and to working with you in developing the FEBS Journal into a leading multidisciplinary journal in the life sciences.
